Validation of multiple myeloma risk stratification indices in
routine clinical practice: Analysis of data from the Czech
Myeloma Group Registry of Monoclonal Gammopathies

J 2018

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

RADOCHA, Jakub, Vladimír MAISNAR, Luděk POUR, Ivan ŠPIČKA, Jiří MINAŘÍK et. al.

Základní údaje

Originální název

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

Autoři

RADOCHA, Jakub (203 Česká republika, garant), Vladimír MAISNAR (203 Česká republika), Luděk POUR (203 Česká republika, domácí), Ivan ŠPIČKA (203 Česká republika), Jiří MINAŘÍK (203 Česká republika), Lenka SZELIGOVÁ (203 Česká republika), Petr PAVLÍČEK (203 Česká republika), Alexandra JUNGOVÁ (203 Česká republika), Marta KREJČÍ (203 Česká republika, domácí), Tomáš PIKA (203 Česká republika), Jan STRAUB (203 Česká republika), Lucie BROŽOVÁ (203 Česká republika, domácí), Lukáš STEJSKAL (203 Česká republika), Adriana HEINDORFER (203 Česká republika), Pavel JINDRA (203 Česká republika), Petr KESSLER (203 Česká republika), Peter MIKULA (203 Česká republika), Michal SYKORA (203 Česká republika), Marek WRÓBEL (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí) a Roman HAJEK (203 Česká republika)

Vydání

Cancer Medicine, Houston, John Wiley & Sons Ltd. 2018, 2045-7634

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.357

Kód RIV

RIV/00216224:14110/18:00104185

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1002/cam4.1620

UT WoS

000441430100054

Klíčová slova anglicky

Czech Myeloma Group Registry; monoclonal gammopathies; multiple myeloma; overall survival; real-world; risk stratification

Štítky

14110212, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 2. 2019 15:54, Soňa Böhmová

Anotace

V originále

This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised International Staging System (R-ISS) indices for risk stratification in patients with multiple myeloma (MM) in clinical practice. Patients were included if they had symptomatic MM, complete data allowing R-ISS and IMWG staging (including cytogenetic information regarding t(4;14), t(14;16), and del(17p)), and key parameters for treatment evaluation. Median overall survival (OS) in included patients (n = 550) was 47.7 (95% CI: 39.5-55.9) and 46.2 (95% CI: 38.9-53.5) months from diagnosis and initiation of first-line therapy, respectively. Patients categorized as higher vs lower risk had reduced survival; median OS from diagnosis was 35.4 (95% CI: 30.5-40.3) vs 58.3 (95% CI: 53.8-62.9) months in high-risk vs other patients (IMWG; P = .001) and 34.1 (95% CI: 30.2-38.0) vs 47.2 (95% CI: 43.4-51.0) months in Stage III vs Stage II patients (R-ISS; P < .001). In conclusion, IMWG and R-ISS risk stratification indices are applicable to patients with MM in a real-world setting.

Citovat

RADOCHA, Jakub, Vladimír MAISNAR, Luděk POUR, Ivan ŠPIČKA, Jiří MINAŘÍK, Lenka SZELIGOVÁ, Petr PAVLÍČEK, Alexandra JUNGOVÁ, Marta KREJČÍ, Tomáš PIKA, Jan STRAUB, Lucie BROŽOVÁ, Lukáš STEJSKAL, Adriana HEINDORFER, Pavel JINDRA, Petr KESSLER, Peter MIKULA, Michal SYKORA, Marek WRÓBEL, Jiří JARKOVSKÝ a Roman HAJEK. Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. Cancer Medicine. Houston: John Wiley & Sons Ltd., 2018, roč. 7, č. 8, s. 4132-4145. ISSN 2045-7634. Dostupné z: https://dx.doi.org/10.1002/cam4.1620.

@article{1455076,
   author = {Radocha, Jakub and Maisnar, Vladimír and Pour, Luděk and Špička, Ivan and Minařík, Jiří and Szeligová, Lenka and Pavlíček, Petr and Jungová, Alexandra and Krejčí, Marta and Pika, Tomáš and Straub, Jan and Brožová, Lucie and Stejskal, Lukáš and Heindorfer, Adriana and Jindra, Pavel and Kessler, Petr and Mikula, Peter and Sykora, Michal and Wróbel, Marek and Jarkovský, Jiří and Hajek, Roman},
   article_location = {Houston},
   article_number = {8},
   doi = {http://dx.doi.org/10.1002/cam4.1620},
   keywords = {Czech Myeloma Group Registry; monoclonal gammopathies; multiple myeloma; overall survival; real-world; risk stratification},
   language = {eng},
   issn = {2045-7634},
   journal = {Cancer Medicine},
   title = {Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies},
   volume = {7},
   year = {2018}
}

TY  - JOUR
ID  - 1455076
AU  - Radocha, Jakub - Maisnar, Vladimír - Pour, Luděk - Špička, Ivan - Minařík, Jiří - Szeligová, Lenka - Pavlíček, Petr - Jungová, Alexandra - Krejčí, Marta - Pika, Tomáš - Straub, Jan - Brožová, Lucie - Stejskal, Lukáš - Heindorfer, Adriana - Jindra, Pavel - Kessler, Petr - Mikula, Peter - Sykora, Michal - Wróbel, Marek - Jarkovský, Jiří - Hajek, Roman
PY  - 2018
TI  - Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies
JF  - Cancer Medicine
VL  - 7
IS  - 8
SP  - 4132-4145
EP  - 4132-4145
PB  - John Wiley & Sons Ltd.
SN  - 20457634
KW  - Czech Myeloma Group Registry
KW  - monoclonal gammopathies
KW  - multiple myeloma
KW  - overall survival
KW  - real-world
KW  - risk stratification
N2  - This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised International Staging System (R-ISS) indices for risk stratification in patients with multiple myeloma (MM) in clinical practice. Patients were included if they had symptomatic MM, complete data allowing R-ISS and IMWG staging (including cytogenetic information regarding t(4;14), t(14;16), and del(17p)), and key parameters for treatment evaluation. Median overall survival (OS) in included patients (n = 550) was 47.7 (95% CI: 39.5-55.9) and 46.2 (95% CI: 38.9-53.5) months from diagnosis and initiation of first-line therapy, respectively. Patients categorized as higher vs lower risk had reduced survival; median OS from diagnosis was 35.4 (95% CI: 30.5-40.3) vs 58.3 (95% CI: 53.8-62.9) months in high-risk vs other patients (IMWG; P = .001) and 34.1 (95% CI: 30.2-38.0) vs 47.2 (95% CI: 43.4-51.0) months in Stage III vs Stage II patients (R-ISS; P < .001). In conclusion, IMWG and R-ISS risk stratification indices are applicable to patients with MM in a real-world setting.
ER  -

RADOCHA, Jakub, Vladimír MAISNAR, Luděk POUR, Ivan ŠPIČKA, Jiří MINAŘÍK, Lenka SZELIGOVÁ, Petr PAVLÍČEK, Alexandra JUNGOVÁ, Marta KREJČÍ, Tomáš PIKA, Jan STRAUB, Lucie BROŽOVÁ, Lukáš STEJSKAL, Adriana HEINDORFER, Pavel JINDRA, Petr KESSLER, Peter MIKULA, Michal SYKORA, Marek WRÓBEL, Jiří JARKOVSKÝ a Roman HAJEK. Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. \textit{Cancer Medicine}. Houston: John Wiley \&{} Sons Ltd., 2018, roč.~7, č.~8, s.~4132-4145. ISSN~2045-7634. Dostupné z: https://dx.doi.org/10.1002/cam4.1620.

Podrobný výpis o publikaci